1. Introduction {#sec1}
===============

Patients with Parkinson\'s disease (PD) experience weight loss in the advanced stages of the disease, resulting in a reduction in body mass index (BMI) \[[@B1]--[@B3]\]. Weight loss appears to involve mainly adipose tissue and to spare (or even increase) fat-free mass \[[@B4], [@B5]\] although not all findings reported in the literature are consistent with this conclusion \[[@B6]\].

Reductions in the most common cardiovascular risk factors (elevated concentrations of fasting glucose, LDL cholesterol, triglycerides, and arterial hypertension) have been recorded in PD patients \[[@B7], [@B8]\] as well as an improvement in HDL cholesterol \[[@B9]\]. The pathogenetic mechanisms involved have not been elucidated. According to some authors, the phenomenon may be induced by the modulating activity of levodopa therapy on the sympathetic system \[[@B10]\].

It has been shown that there is a relationship between adipose tissue and cardiovascular risk mediated by adipokines, such as adiponectin. Adiponectin is a protein synthesized by white fat tissue, whose concentrations in human serum range from 3 to 30 *μ*g/mL \[[@B11]--[@B14]\]. High serum adiponectin concentrations, which are influenced by a reduction in fat mass \[[@B11]\], are associated with a reduction in the risk of myocardial infarction, even after adjustment for HDL, LDL, and BMI levels \[[@B15]\], whereas low-adiponectin concentrations are associated with the risk of developing type II diabetes \[[@B16]\] and hypertension \[[@B17]\]. It is well known that adiponectin exerts important vascular and cardiac effects, especially in preserving endothelial function, protecting it from ischemic and reperfusion damage, and in stimulating angiogenesis; it also possesses anti-inflammatory, antiapoptotic and antihypertrophic properties \[[@B18]\]. Furthermore, it modulates inflammation, reducing the synthesis of proinflammatory cytokines, such as TNF*α* \[[@B19]\]. Overall, it, therefore, appears that adiponectin has antiatherogenic effects that could explain how it is able to reduce cardiovascular risk.

To date, the data reported in the literature on adiponectin concentrations are related to the general population or to subjects with different degrees of obesity, diabetes, and/or dyslipidemia. To our knowledge, no data in PD patients exist.

The objective of our study was to determine serum adiponectin concentrations in a group of PD patients in advanced stages of the disease \[[@B20], [@B21]\], to assess whether there is a correlation between adiponectin concentrations, body composition, and metabolic markers in this patient population.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

We recruited 30 patients suffering from PD admitted to the Parkinson Institute (Istituti Clinici di Perfezionamento (ICP) Hospital, Milan, Italy) consecutively. PD was diagnosed according to UK Brain Bank criteria \[[@B22]\]. All enrolled patients were on treatment with levodopa and a dopamine agonist for neurological symptoms. No patients were on treatment prescribed to decrease total cholesterol levels. Patients had a mean duration of PD of 8.7 ± 6.1 years (range 5--20 years).

Twenty-eight morbidly obese subjects (14 males, 14 females; mean ± SD age 68.4 ± 11 years, mean ± SD body mass index (BMI, kg/m^2^) 43.5 ± 5.3) were enrolled in the study. Due to the higher degree of obesity, some of the obese patients were in treatment with lipid-lowering drugs. Blood samples were obtained in the morning, after an overnight fast.

Thirty-three (22 males and 11 females) normal-weight (BMI 22.9 ± 2), metabolically healthy volunteers, aged 36 ± 6 years, were also enrolled. In this latter group, arterial pressure was assessed, and it was in the normality range for all subjects. They were not on treatment prescribed to decrease total cholesterol levels. They had normal glucose, total cholesterol, and insuline levels. Blood samples were obtained in the morning, after an overnight fast.

2.2. Assessments {#sec2.2}
----------------

All patients underwent assessment of nutritional status.

The nutritional assessments included the following steps:

i.  complete nutritional examination (family history, lifestyle, medical history including pharmacological treatment, dietary history, body weight history, and assessment of any complication of nutritional interest);

ii. body composition evaluation by anthropometric methods (described in the following section);

iii. assessment of nutritional status by measuring biochemical parameters and adiponectin serum level quantification.

During the hospital stay, the patients underwent also a neurological examination designed to fine-tune the diagnosis and adjust treatment accordingly.

The anthropometric assessment included measurement of body weight, height and calculation of body mass index (BMI) and of the main body circumferences (waist at the anterior superior iliac crest and arm).

Venous blood sampling was carried out in the morning, after an overnight fast, for the following laboratory tests:

i.  routine tests: total cholesterol, HDL cholesterol, creatinine, transaminases, blood glucose, triglycerides, and uric acid;

ii. indicators of nutritional status: plasma transferrin, albumin, and total lymphocytes.

The analyses were carried out at the Laboratory of ICP Hospital, according to standard methods.

Total adiponectin levels in serum were determined by an enzyme-linked immunoabsorbent assay (ELISA Total Human Adiponectin Kit, TECOmedical GROUP, Sissach, Switzerland). Total adiponectin detection limit was 1.56--100 ng/mL.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Patients involved in the study were numbered progressively, and the relative anonymous data were used for the creation of a database protected by password. The following variables were collected: body weight (kg), height (meters), BMI (Kg/m^2^), waist circumference (cm), arm circumference (cm), blood glucose (mg/dL), total cholesterol (mg/dL), HDL cholesterol (mg/dL), triglycerides (mg/dL), creatinine (mg/dL), albumin (g/dL), transferrin (mg/dL), AST (U/L), ALT (U/L), duration of disease (years), daily intake of levodopa (mg), and adiponectin (*μ*g/mL).

A Shapiro-Wilk W-test was performed systematically to test the normality of data distribution. In case of lack of normality, data were log-transformed. The statistical analysis of data was carried out using JMP software, version 3.2.6, SAS Institute Inc, USA. A *P*-value \<.05 was the set limit for statistical significance. Means were compared using ANOVA/Student\'s *t*-test, and Pearson\'s test was used to assess correlations between two variables at a time. The patient population was subdivided into two groups according to whether their HDL cholesterol was above or below the threshold for protection against cardiovascular disease: ≥50 mg/dL (PD HDL-high group) and \<50 mg/dL (PD HDL-low group). To analyze this comparison, Wilcoxon test (for non parametric data) and/or ANOVA test were used.

3. Results {#sec3}
==========

The biochemical and clinical features of the studied PD patients are summarized in [Table 1](#tab1){ref-type="table"}. Most of the patients were males (64%). No differences between genders were recorded, except for an anthropometric parameter, such as waist circumference (*P* = .02) and fat mass/fat-free mass percentage (*P* \< .05), as expected. Adiponectin serum concentrations in PD patients were on average 9.59 ± 5.9 *μ*g/mL (mean ± SD) with an interquartile range of 5.92--12.9 *μ*g/mL.

In PD patients, the adiponectin serum levels were similar to adiponectin serum levels in normal-weight, healthy subjects (9.02 ± 6.7 *μ*g/mL) but significantly higher than those recorded in an aged-matched group of morbidly obese subjects (6 ± 2.9 *μ*g/mL), as shown in [Figure 1(a)](#fig1){ref-type="fig"}. In PD patients, a significant positive correlation was found between serum adiponectin and HDL cholesterol concentrations ([Figure 1(b)](#fig1){ref-type="fig"}) (Rho = 0.53, *P* = .003) which remained significant even after adjustment for gender, age, and duration of disease. In the PD patient group, there was an inverse correlation between adiponectin serum levels and waist circumference (Rho = −0.37, *P* = .05), body weight (Rho = −0.47, *P* = .009), fasting glucose concentrations (Rho = −0.47, *P* = .01), and triglyceride concentrations (Rho = −0.48, *P* = .01). No correlation was observed between adiponectin serum levels and BMI, nor between adiponectin and fat mass fat-free mass percentage.

The association between high levels of HDL cholesterol and a decreased risk for cardiovascular disease has been well established through epidemiological and clinical studies. We then decided to analyze our patients regrouped for HDL cholesterol levels: patients with HDL ≥ 50 mg/dL were in the PD HDL-high group while patients with HDL \< 50 mg/dL were in the PD HDL-low group. Sixteen PD patients belonged to the PD HDL-high group (HDL ≥ 50 mg/dL) and 14 to the PD HDL-low group (HDL \< 50 mg/dL). These two subgroups did not differ in terms of age, duration of disease, levodopa dosage, and total cholesterol concentrations. Serum adiponectin concentrations were significantly higher in the PD HDL-high group (*P* = .02), and BMI, body weight, and fasting glucose levels were significantly lower in the PD HDL-high group ([Figure 2](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

The adiponectin serum levels in PD patients were similar to the adiponectin serum levels in young, healthy, normal-weight subjects matched for BMI. Moreover, a correlation between adiponectin serum levels and HDL cholesterol concentrations was found. The finding of a direct correlation between adiponectin and HDL cholesterol concentrations is consistent with the known antiatherogenic properties of adiponectin protein \[[@B18]\]. Low levels of adiponectin are associated with low levels of HDL cholesterol and this combination might be an independent cardiovascular risk factor; on the other hand, high levels of adiponectin are associated with high levels of HDL cholesterol indicating protection against cardiovascular events. The growing body of data suggests that adiponectin reduces cardiovascular risk in the general population, that is, the risk of developing type II diabetes, hypertension, and myocardial infarction \[[@B15]--[@B17]\]. To our knowledge, this is the first study in which adiponectin serum levels have been measured in PD patients. There is some evidence suggesting that PD patients body weight is lower than age-matched healthy subjects \[[@B2]\]. We then decided to compare adiponectin levels in PD patients with a BMI-matched group, despite a significant difference in mean age. Interestingly, adiponectin serum levels were not different in the two groups taken into consideration, indicating that adiponectin might play a role as a protective factor against cardiovascular disease also in PD patients. Previous studies were performed in the general population, focusing on differences between obese and nonobese subjects, and between genders. It has been established that in the general population, the synthesis of adiponectin is stimulated when the quantity of adipose tissue diminishes \[[@B23]\], contrary to most other adipokines, whose synthesis is directly proportional to the increase in fat mass. To date, the normal range for adiponectin serum levels has not been established. The mean value of serum adiponectin concentrations in nonobese subjects is about 10 *μ*g/mL; concentrations are lower by more than 50% in obese subjects \[[@B24], [@B25]\], taking into account differences linked to genders. We decided to compare adiponectin levels in a morbidly obese patient group, age-matched with the PD group. We observed that adiponectin levels in obese subjects were significantly decreased. Obesity is one of the first cardiovascular risk factors, and the reduction in adiponectin levels may have a role in this increased risk.

It is known that adiponectin serum concentrations differ between genders: in nonobese subjects, mean serum levels in men are lower than that in women (7.7 ± 3.1 versus 10.6 ± 7.3 *μ*g/mL). This difference between genders may be due to androgen effects \[[@B26]\], which occur also in obese subjects \[[@B24]\]. A larger group is needed to address this issue in PD patients.

In the present study, we performed a comparison for adiponectin levels in PD patients with the levels of an age-matched group of obese patients on one hand and with the circulating levels of a BMI-matched healthy control group on the other hand. Since adiponectin is decreased in obesity, in the comparison with PD patients, adiponectin levels of PD patients were as expected increased.

However, the levels in PD patients were not different when compared to healthy and young controls. With this kind of comparison it is hard to know whether the high adiponectin levels in PD patients are simply a reflection of body weight and body composition, or are intrinsically different in PD subjects. A future study, in a bigger cohort, both age- and BMI- matched, is needed to clarify this issue.

One issue in research on adiponectin is what form to measure in the bloodstream. In human serum, it occurs in the form of various oligomers: trimer, hexamer, and high molecular weight forms \[[@B27], [@B28]\]. Both biological activity and the translation mechanism differ from multimer to multimer, but it has been shown beyond doubt that the active form is the high molecular weight adiponectin \[[@B29], [@B30]\]. Much more work is required to establish which isoforms of adiponectin are associated with cardioprotection and to clarify the transduction mechanisms of receptor-mediated signals.

The clinical usefulness of adiponectin as a diagnostic/prognostic marker has yet to be established according to the outcome of prospective clinical trials. In particular, information is needed on the predictive value of adiponectin serum concentrations as compared to other well-known risk factors. Thus, it is too early to propose the introduction of adiponectin serum concentrations as a biomarker in clinical practice. However, this adipokine appears to be an important factor to study not only as a potential diagnostic index for cardiovascular risk, but also as a target for pharmacological therapy \[[@B31]\].

The correlation we found between adiponectin and HDL cholesterol suggests that cardiovascular risk is low in PD patients. In a previous study, we observed a correlation between the duration of disease and HDL cholesterol concentrations \[[@B9]\]. The lower limit of normal for HDL cholesterol serum concentrations is usually considered 50 mg/dL \[[@B32]\]. For this reason, we decided to subdivide our patient population into two groups according to this cut-off value, which separated patients with normal values (PD HDL-high) from those with lower abnormal values (PD HDL-low). PD patients with HDL cholesterol ≥50 mg/dL resulted to have better metabolic protection (and higher adiponectin levels) as well as normal BMI and fasting glucose levels. High-density lipoprotein (HDL) cholesterol is a common and independent protective cardiovascular risk factor. Cardiovascular risk increases as HDL cholesterol levels decrease. While lipid lowering and antidiabetic drugs, such as statins, fibrates, and PPAR gamma agonists as well as diet alone have only marginal effects on HDL cholesterol serum levels. On the contrary, physical exercise is able to elevate HDL levels effectively.

5. Conclusions {#sec5}
==============

In conclusion, this is the first study that shows that PD patients have serum adiponectin concentrations elevated and comparable to the levels of young normal-weight subjects with absence of cardiovascular risk factors. Moreover, the adiponectin concentrations are related to HDL cholesterol levels.
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![(a) adiponectin serum levels (*μ*g/mL) in normal-weight PD and OB subjects. Mean ± SD, are shown. \*\**P*-value \<.01. (b) correlation between adiponectin serum levels (*μ*g/mL) and HDL cholesterol levels (mg/dL) in PD patients (*n* = 30) (Rho = 0.53, *P* = .003).](PD2011-624764.001){#fig1}

![PD patient (*n* = 30) subgroups based on HDL cholesterol levels: PD HDL-high (HDL cholesterol ≥ 50 mg/mL, *n* = 16) and PD HDL-low (HDL cholesterol \< 50 mg/mL, *n* = 14). Significant differences in means (±SD) for adiponectin (*μ*g/mL), fasting glucose (mg/dL), body weight (kg), and BMI (kg/m^2^) are shown. \**P*-value \<.05; \*\**P*-value \<.01.](PD2011-624764.002){#fig2}

###### 

Biochemical, anthropometric, and clinical characteristics of the Parkinson disease (PD) patient population enrolled, *n* = 30, *M*/*F* = 19(64%)/11(36%). Data are expressed as mean ± SD.

  Parameter                     Data (mean ± standard deviation)
  ----------------------------- ----------------------------------
  Age (years)                   62.4 ± 10.63
  Duration of disease (years)   8.7 ± 6.1
  Levodopa (mg)                 532.7 ± 220.1
  BMI (Kg/m^2^)                 25.5 ± 4.2
  Weight (Kg)                   71.8 ± 15.7
  Waist circumference (cm)      95.23 ± 15.8
  Arm circumference (cm)        28.4 ± 3.97
  Fat mass (%)                  32.3 ± 7.74
  Fat-free mass (%)             67.7 ± 6.7
  Albumin (g/dL)                3.89 ± 0.2
  Transferrin (mg/dL)           243.6 ± 40.5
  Creatinine (mg/dL)            0.67 ± 0.1
  ALT (U/L)                     13.5 ± 6.6
  AST (U/L)                     16.8 ± 4.9
  Triglycerides (mg/dL)         97.5 ± 46.3
  Glucose (mg/dL)               87.5 ± 14.9
  Total cholesterol (mg/dL)     189.0 ± 46.21
  HDL cholesterol (mg/dL)       51.8 ± 16.4
  Adiponectin (*μ*g/mL)         9.59 ± 5.97
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